These findings are consistent with those of previous research. Patients with schizophrenia are frequently obese, and over time, weight gain increases the risk of cardiovascular lesions, and is a factor that can contribute to a worse vital prognosis. This issue has therefore become of particular concern [Haupt, 2006; Newcomer and Haupt, 2006]. Our findings showed that

switching from oral risperidone to RLAI, either in older or younger patients, resulted in virtually no change in body weight. In addition, BMI remained below 23, the level for normal body weight, suggesting that the risk of weight gain with RLAI switching is not high. These results Inhibitors,research,lifescience,medical are also consistent with those of previous research [Chue et al. 2005; Lasser et al. 2004; Newcomer and Haupt, 2006]. Switching from oral risperidone Inhibitors,research,lifescience,medical to RLAI resulted in similar (though not significant) reductions in total cholesterol, which is a risk factor for cardiovascular disease in both older and younger patients. Switching from oral risperidone to RLAI also resulted in a reduction (though not significant) in neutral lipids, which are an independent risk factor for coronary artery disease, in older patients compared with the control group who continued on oral risperidone. The results of this study therefore show that in older and younger patients switching from oral risperidone to RLAI resulted in a smaller effect

on the lipid-metabolizing Inhibitors,research,lifescience,medical system than in the control group that was continued on oral risperidone. These findings are also consistent with those of previous research [Lasser et al. 2004; Tschoner et al. 2009].

Hyperprolactinaemia is a factor that can result in sexual dysfunction, one of the primary causes of reduced QOL [Baggaley, 2008], and risperidone-induced hyperprolactinaemia Inhibitors,research,lifescience,medical is dose dependent [Dossenbach Inhibitors,research,lifescience,medical et al. 2006]. The results of this study suggest that, in older patients, switching from oral risperidone to RLAI, with the same reduction in the risperidone equivalent dose as in younger patients, may result in a significant reduction in prolactin levels compared with the control group who continued on oral risperidone. In this study, we converted the doses of antipsychotic medications before and after RLAI switching to risperidone equivalents to investigate changes in the risperidone equivalent dose. The results show that the almost older patients who were switched realized a significant decrease compared with the control group, although no significant difference was found compared with the younger patients who were switched to RLAI. Since older patients generally have reduced liver and kidney function and are thus more susceptible to adverse drug reactions, every effort must be made to reduce the dosing levels that are used in older patients. RLAI switching was also confirmed to result in a reduction in the dose in an overseas this website clinical study [Schmauss et al. 2007].